Biblio

Found 7 results
Filters: Keyword is Treatment Outcome  [Clear All Filters]
2022
Tang X, Brinton RDiaz, Chen Z, Farland LV, Klimentidis Y, Migrino R, Reaven P, Rodgers K, Zhou JJ.  2022.  Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.. BMJ Open Diabetes Res Care. 10(5)
2020
Wang Y, Hernandez G, Mack WJ, Schneider LS, Yin F, Brinton RD.  2020.  Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy.. Menopause. 27(1):57-65.
2018
Zhang H, Lund DM, Ciccone HA, Staatz WD, Ibrahim MM, Largent-Milnes TM, Seltzman HH, Spigelman I, Vanderah TW.  2018.  Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.. Pain. 159(9):1814-1823.
2013
Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S et al..  2013.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.. J Pharmacol Exp Ther. 347(1):7-19.
2011
North American Menopause Society.  2011.  The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).. Menopause. 18(7):732-53.
2005
D Sparks L, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C.  2005.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.. Arch Neurol. 62(5):753-7.
D Sparks L, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J et al..  2005.  Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.. Curr Alzheimer Res. 2(3):343-53.